Patents by Inventor Crystal Conn

Crystal Conn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress
    Publication number: 20220152035
    Abstract: In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2? axis of the UPR adaptive response. Agents that disrupt PERK-eIF2? pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 19, 2022
    Applicant: The Regents of the University of California
    Inventors: Davide Ruggero, Hao Nguyen, Peter Carroll, Crystal Conn
  • Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
    Patent number: 11253522
    Abstract: In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2? axis of the UPR adaptive response. Agents that disrupt PERK-eIF2? pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.
    Type: Grant
    Filed: April 28, 2019
    Date of Patent: February 22, 2022
    Assignee: The Regents of the University of California
    Inventors: Davide Ruggero, Hao Nguyen, Peter Carroll, Crystal Conn
  • Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress
    Publication number: 20190328740
    Abstract: In cancers such as prostate cancer, the combination of PTEN loss and activation of Myc activates an adaptive stress response that enables tumor cells to escape the stress of massively upregulated protein synthesis. This pro-survival response is mediated by the PERK-phosphorylated eIF2? axis of the UPR adaptive response. Agents that disrupt PERK-eIF2? pathways disrupt the adaptive response and lead to cancer cell death from uncontrolled growth. For example, ISRIB and derivatives may be employed as therapeutic agents to disrupt PERK-mediated adaptive mechanisms. Additionally PTEN loss and activation of Myc provides a diagnostic marker that enables better prognosis and the selection of amenable treatments.
    Type: Application
    Filed: April 28, 2019
    Publication date: October 31, 2019
    Inventors: Davide Ruggero, Nguyen Hao, Peter Carroll, Crystal Conn